Compare Enveric Biosciences Inc (ENVB) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs MPLX LP — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while MPLX LP trades at $57.42 (market cap $57.84B). The key difference: MPLX LP is far larger — about 8645.7× Enveric Biosciences Inc's market cap, and MPLX LP pays a 7.55% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | MPLX | |
|---|---|---|
Market Cap | $6.69M | $57.84B |
Volume | 41,141 | 1,104,749 |
Sector | Health | Energy |
52-Week High | $10.80 | $60.51 |
52-Week Low | $1.27 | $47.80 |
Typical Hold Time | 14 Days | — |
Enterprise Value | -$1.60M | $82.94B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong profitability with 40.45% net income margin and 33.95% ROE, though recent earnings missed expectations in two consecutive quarters. Analyst consensus remains strongly bullish with a $63.80 price target, representing 12% upside potential. Recent news highlights MPLX's resilience in volatile energy markets through fee-based revenue models and strong distribution coverage.
The outlook remains positive given strong cash flow generation and dividend sustainability, though risks include energy market volatility and recent earnings misses. With 68% analyst buy ratings and solid fundamentals, MPLX presents a compelling income opportunity despite near-term technical weakness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
